Real-World Study of Guselkumab for Ulcerative Colitis and Crohn's Disease
Part of Digestive system clinical trials.
This study tracks how guselkumab (a biologic medication that reduces inflammation) works in patients with moderate-to-severe ulcerative colitis or Crohn's disease in Saudi Arabia. Researchers want to understand how the medication helps patients in everyday clinical practice, not in a controlled research setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of moderate-to-severe ulcerative colitis or Crohn's disease
- Your doctor has decided you should start guselkumab and you haven't received your first dose yet
- You have never taken other IL-23 inhibitor medications (like risankizumab or mirikizumab)
- You have not received more than 4 different biologic or small-molecule treatments for your inflammatory bowel disease
- You are able and willing to sign a consent form and allow your medical records to be reviewed
- You are not contraindicated to guselkumab based on the medication label
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study looks at how well guselkumab (Tremfya) works for people with moderate to severe Crohn's disease or ulcerative colitis when used in everyday medical practice. It collects information from patients who are prescribed this medicine to better understand its long-term effects and safety.
This study tracks how well guselkumab (a biologic medication that blocks IL-23, a protein that drives inflammation) works for moderate-to-severe ulcerative colitis or Crohn's disease in everyday clinical practice. Researchers want to understand long-term benefits and safety in real patients.
This study looks at how well guselkumab (Tremfya), a treatment for Crohn's disease and ulcerative colitis, works in everyday patients. Researchers will review medical records to see how long people stay on the medicine and how it helps their symptoms.
This study looks at how well guselkumab (Tremfya) works for people with moderate-to-severe Crohn's disease or ulcerative colitis in everyday medical practice in Italy. If you qualify, you will receive the treatment normally prescribed by your doctor and help researchers track its real-world effectiveness.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
Hear when a new Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.